Citigroup’s Alder Biopharmaceuticals ALDR Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2019
Q4 | – | Sell |
-973,604
| Closed | -$18.4M | – | 7958 |
|
|
2019
Q3 | $18.4M | Buy |
973,604
+737,892
| +313% | +$8.44M | 0.01% | 963 |
|
|
2019
Q2 | $2.77M | Buy |
235,712
+217,638
| +1,204% | +$2.63M | ﹤0.01% | 2507 |
|
|
2019
Q1 | $247K | Sell |
18,074
-313,862
| -95% | -$4.07M | ﹤0.01% | 4904 |
|
|
2018
Q4 | $3.4M | Buy |
331,936
+200,294
| +152% | +$2.56M | ﹤0.01% | 2181 |
|
|
2018
Q3 | $2.19M | Buy |
131,642
+109,843
| +504% | +$1.99M | ﹤0.01% | 2643 |
|
|
2018
Q2 | $345K | Sell |
21,799
-31,373
| -59% | -$477K | ﹤0.01% | 4482 |
|
|
2018
Q1 | $675K | Sell |
53,172
-66,378
| -56% | -$960K | ﹤0.01% | 3674 |
|
|
2017
Q4 | $1.37M | Sell |
119,550
-5,570
| -4% | -$62.2K | ﹤0.01% | 3026 |
|
|
2017
Q3 | $1.53M | Buy |
125,120
+91,687
| +274% | +$956K | ﹤0.01% | 2935 |
|
|
2017
Q2 | $383K | Buy |
33,433
+24,765
| +286% | +$458K | ﹤0.01% | 4226 |
|
|
2017
Q1 | $180K | Sell |
8,668
-114,287
| -93% | -$2.53M | ﹤0.01% | 4749 |
|
|
2016
Q4 | $2.56M | Buy |
122,955
+106,792
| +661% | +$2.78M | ﹤0.01% | 2646 |
|
|
2016
Q3 | $530K | Buy |
16,163
+6,244
| +63% | +$190K | ﹤0.01% | 3847 |
|
|
2016
Q2 | $248K | Sell |
9,919
-11,714
| -54% | -$317K | ﹤0.01% | 4302 |
|
|
2016
Q1 | $530K | Buy |
21,633
+15,148
| +234% | +$351K | ﹤0.01% | 4055 |
|
|
2015
Q4 | $215K | Sell |
6,485
-14,841
| -70% | -$502K | ﹤0.01% | 4683 |
|
|
2015
Q3 | $699K | Buy |
21,326
+13,944
| +189% | +$593K | ﹤0.01% | 3427 |
|
|
2015
Q2 | $391K | Buy |
7,382
+1,397
| +23% | +$50.8K | ﹤0.01% | 3935 |
|
|
2015
Q1 | $172K | Sell |
5,985
-1,832
| -23% | -$50.3K | ﹤0.01% | 4653 |
|
|
2014
Q4 | $227K | Sell |
7,817
-60,280
| -89% | -$1.08M | ﹤0.01% | 4575 |
|
|
2014
Q3 | $863K | Buy |
68,097
+68,029
| +100,043% | +$1.03M | ﹤0.01% | 3116 |
|
|
2014
Q2 | $1K | Buy |
+68
| New | +$957 | ﹤0.01% | 7006 |
|
Citigroup's ALDR Position: Q4 2019 in Review
Citigroup sold out of Alder Biopharmaceuticals (ALDR) in Q4 2019, closing a stake of 973,604 shares — an estimated $18.4M sold.
Citigroup first reported a position in ALDR in Q2 2014 and held it in 22 quarters. The position peaked at $18.4M in Q3 2019. 0 funds tracked by Wall St. Rank hold ALDR as of Q4 2019.
- Citigroup reported no remaining Alder Biopharmaceuticals position as of Q4 2019 after selling out during the quarter.
- Citigroup sold 973,604 Alder Biopharmaceuticals shares in Q4 2019, an estimated $18.4M.
- Citigroup first reported a position in Alder Biopharmaceuticals in Q2 2014 and held it in 22 quarters.
- Citigroup's Alder Biopharmaceuticals position peaked at $18.4M in Q3 2019.
- 0 funds tracked by Wall St. Rank held Alder Biopharmaceuticals as of Q4 2019.
Based on Citigroup's 13F filing for Q4 2019, filed 12 Feb 2020.